title: Estimating the long-term effects of HPV vaccination in Germany.
abstract: In Germany, vaccination against the most oncogenic HPV types 16/18 is recommended by the Standing Committee on Vaccination (STIKO) for 12-17 year old girls since March 2007. We developed a dynamic mathematical model for the natural history and transmission of HPV infections to estimate the impact of vaccination on incidence and mortality of cervical cancer and its pre-stages, and on anogenital warts. We focused on an extensive model calibration to epidemiologic data for all stages of the natural history model as well as on a detailed implementation of cervical cancer screening modalities in Germany. Our model predicts first a substantial reduction of cervical cancer incidence and mortality over the next 30 years, which is mainly attributable to an increase in screening participation in the 1990s and not to HPV vaccination, followed by a further reduction attributable to vaccination. Over the next 100 years, HPV vaccination will prevent approximately 37% of cervical cancer cases even if vaccination coverage is only 50% (as currently observed in Germany). Consideration of cross-protection results in a further reduction of approximately 7% of all cervical cancer cases for the bivalent and about 5% for the quadrivalent vaccine in our model. Vaccination of boys was only reasonable if moderate to high vaccination coverage in girls was not achieved. Strategies should be implemented in Germany to increase HPV vaccination coverage among girls thereby making better use of the demonstrated benefits of the vaccine.
authors.affiliation: Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Horn
authors.forename: O
authors.initials: O
authors.lastname: Damm
authors.forename: M E E
authors.initials: ME
authors.lastname: Kretzschmar
authors.forename: Y
authors.initials: Y
authors.lastname: Deleré
authors.forename: O
authors.initials: O
authors.lastname: Wichmann
authors.forename: A M
authors.initials: AM
authors.lastname: Kaufmann
authors.forename: E
authors.initials: E
authors.lastname: Garbe
authors.forename: A
authors.initials: A
authors.lastname: Krämer
authors.forename: W
authors.initials: W
authors.lastname: Greiner
authors.forename: R T
authors.initials: RT
authors.lastname: Mikolajczyk
mesh_terms: D000293:Adolescent; D002648:Child; D003218:Condylomata Acuminata / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D056738:Cross Protection; D005260:Female; D005544:Forecasting; D005858:Germany / Q000453:epidemiology; D052162:Human papillomavirus 16 / Q000276:immunology; D052161:Human papillomavirus 18 / Q000276:immunology; D006801:Humans; D015994:Incidence; D008297:Male; D008962:Models, Theoretical; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000401:mortality* / Q000517:prevention & control*; D014611:Vaccination
chemical_list: D053918:Papillomavirus Vaccines